RA
TVRD

Royce & Associates’s Tvardi Therapeutics TVRD Stock Holding History

Royce & Associates’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,619
Closed -$340K – 948
2023
Q3 		$340K Hold
5,619
– – ﹤0.01% 841
2023
Q2 		$573K Hold
5,619
– – 0.01% 823
2023
Q1 		$993K Hold
5,619
– – 0.01% 763
2022
Q4 		$2.17M Sell
5,619
-330
-6% -$125K 0.02% 632
2022
Q3 		$2M Buy
5,949
+3,156
+113% +$1.14M 0.02% 625
2022
Q2 		$918K Sell
2,793
-307
-10% -$108K 0.01% 761
2022
Q1 		$1.36M Buy
3,100
+2,733
+745% +$1.12M 0.01% 775
2021
Q4 		$161K Sell
367
-54
-13% -$27.1K ﹤0.01% 950
2021
Q3 		$234K Buy
+421
New +$211K ﹤0.01% 962

Other funds holding TVRD

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $626M AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return